清洁产品

Search documents
珀莱雅股价上涨1.75% 公司回购注销24.2万股限制性股票
Jin Rong Jie· 2025-08-18 17:37
Group 1 - The stock price of Proya reached 84.50 yuan as of the close on August 18, 2025, with an increase of 1.45 yuan, representing a rise of 1.75% [1] - The trading volume on that day was 102,835 hands, with a turnover of 868 million yuan and a fluctuation of 3.29% [1] - Proya is primarily engaged in the research, production, and sales of cosmetics, covering various categories such as skincare, makeup, and cleansing [1] Group 2 - On the evening of August 18, the company announced the repurchase and cancellation of 242,424 restricted stocks held by 14 former incentive targets from the 2022 restricted stock incentive plan, with the cancellation date set for August 21, 2025 [1] - On August 18, the net inflow of main funds into Proya was 62.29 million yuan, with a net inflow of 32.09 million yuan over the past five days [1]
重磅!全球医疗巨头百特迎新CEO
Xin Lang Cai Jing· 2025-07-07 15:22
Group 1 - Baxter International Inc. announced the appointment of Andrew Hider as President and CEO, effective no later than September 3, 2025 [1] - Brent Shafer, who has served as Chairman and interim CEO since February 2025, will transition to the role of independent Chairman of the Board [1] Group 2 - Andrew Hider has 25 years of cross-industry experience and a global perspective, focusing on growth-oriented and people-centric leadership [2] - Hider served as CEO and Director of ATS, a leading automation solutions provider, where he significantly improved profit margins and nearly doubled adjusted revenue over five years with a compound annual growth rate (CAGR) in the low double digits [4][5] - Under Hider's leadership, ATS's stock price more than doubled since 2017, outperforming major indices [5] Group 3 - Baxter International, founded in 1931 and headquartered in Deerfield, Illinois, specializes in medical products for chronic and critical care, developing and selling products for complex conditions such as hemophilia and cancer [6] - Baxter's diverse business integrates medical devices, pharmaceuticals, and biotechnology, with a leading position in home kidney therapy and recombinant factor products for bleeding disorders [6] - The company employs approximately 38,000 members globally [6]